ParkourSC buys Quartic to unify AI across life sciences supply chains
What's the deal? ParkourSC has acquired QuarticDealroom has a profile for this one. Try Dealroom →, merging its clinical and commercial supply chain AI with Quartic's manufacturing AI to build a single platform for regulated life sciences and healthcare. Terms were undisclosed. Quartic will now operate as a ParkourSC company.
What each does: ParkourSC provides supply chain intelligence across clinical development, distribution, and point of care. Quartic focuses on manufacturing operations for regulated batch production, including deviation monitoring, Continuous Process Verification, and Expedited Batch Release.
What's the endgame? The combined platform aims to give drugmakers and contract manufacturers a continuous view of a product from its first batch to commercial distribution. It is designed to predict which batches, lots, and shipments are at risk, then recommend actions such as rerouting shipments, prioritising inventory, or accelerating release.
Why it matters: ParkourSC said it can now address four major areas of the life sciences value chain through one platform, effectively doubling its addressable market. The system sits above existing MES, LIMS, QMS, historian, and logistics tools rather than replacing them.
The numbers: The companies, which already share customers, cited documented outcomes including cutting fit-for-use disposition decisions from three days to one minute and improving biologics batch yields by 15% to 20%.
In their words: "The most important facts about a batch are established when it is made, but they are needed long after it leaves the plant," said Rajiv Anand, Quartic's chief executive officer and co-founder. Connecting manufacturing and supply chain data, he said, puts a product's full history in front of the people making release and scale-up decisions.
The signal: The deal reflects a push to consolidate fragmented life sciences software into unified, AI-driven platforms. ParkourSC chief executive officer Mahesh Veerina framed the result as "the definitive standard for autonomous regulated supply chains" — a bet that end-to-end intelligence, not point tools, will define the next phase of pharmaceutical operations.
Read more: pulse2.com
Image credit: Generated with Gemini
